XBIO vs SRZN
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 11, 2026
XBIO
SRZN
Investment Advisor Scores
SRZN
AI Analyst Insights
Detailed Metrics Comparison
| Metric | XBIO | SRZN | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 0 | 0 | Tie |
| PEG Ratio | 0 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 12.0% | 408.6% | SRZN |
| Earnings Growth | 0.0% | -37.0% | XBIO |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 58.5/100 | 34.3/100 | XBIO |
| Profit Margin | -75.9% | 0.0% | SRZN |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | STRONG BUY | AVOID NEW MONEY | XBIO |
Relative Price Performance (Last 90 Days)
Current Technical Phase
XBIO
MarkdownPrice below a falling SMA50 (slope -20.9%), weak momentum, RSI 33
SRZN
MarkupPrice above SMA50, rising 50-day trend (8.5% over 20 days), RSI 60
Fundamentals Snapshot
| Metric | XBIO | SRZN |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -4.9 | -6.7 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 4.1% |
| Gross Margin | 1.0% | -2.6% |
| Operating Margin | -0.8% | -4.9% |
| EPS | -1.15 | -41.94 |
| Dividend Yield | — | — |